A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
Clinical trial NCT04041050 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04041050
- Sponsor
- AbbVie
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-08
- Primary completion
- 2026-12-31
- Enrollment
- 85
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.